{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:25:38Z","timestamp":1792135538720,"version":"4.4.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015760","name":"Inserm Transfert","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015760","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Systemic lupus erythematosus is a complex autoimmune disease during which patients develop autoantibodies raised against nuclear antigens. During the course of the disease, by accumulating in secondary lymphoid organs (SLOs), basophils support autoreactive plasma cells to amplify autoantibody production. We have recently shown that murine lupus-like disease could be controlled by 10\u00a0days of oral treatment with a combination of prostaglandin D<jats:sub>2<\/jats:sub> (PGD<jats:sub>2<\/jats:sub>) receptor (PTGDR) antagonists through the inhibition of basophil activation and recruitment to SLOs. Importantly, inhibiting solely PTGDR-1 or PTGDR-2 was ineffective, and the development of lupus-like disease could only be dampened by using antagonists for both PTGDR-1 and PTGDR-2. Here, we aimed at establishing a proof of concept that a clinically relevant bispecific antagonist of PTGDR-1 and PTGDR-2 could be efficient to treat murine lupus-like nephritis. Diseased Lyn-deficient female mice received treatment with AMG853 (vidupiprant, a bispecific PTGDR-1\/PTGDR-2 antagonist) for 10\u00a0days. This led to the dampening of basophil activation and recruitment in SLOs and was associated with a decrease in plasmablast expansion and immunoglobulin E (IgE) production. Ten days of treatment with AMG853 was consequently sufficient in reducing the dsDNA-specific IgG titers, circulating immune complex glomerular deposition, and renal inflammation, which are hallmarks of lupus-like disease. Thus, bispecific PTGDR-1 and PTGDR-2 antagonists, such as AMG853, are a promising class of drugs for the treatment or prevention of organ damage in systemic lupus erythematosus.<\/jats:p>","DOI":"10.3389\/fimmu.2022.824686","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:40:43Z","timestamp":1649076043000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["AMG853, A Bispecific Prostaglandin D2 Receptor 1 and 2 Antagonist, Dampens Basophil Activation and Related Lupus-Like Nephritis Activity in Lyn-Deficient Mice"],"prefix":"10.3389","volume":"13","author":[{"given":"Christophe","family":"Pellefigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Tchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaimae","family":"Saji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Lamri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic Lupus Erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/antib5010002","article-title":"Autoantibodies in SLE: Specificities, Isotypes and Receptors","volume":"5","author":"Dema","year":"2016","journal-title":"Antibodies (Basel)"},{"key":"B3","article-title":"Advances in Mechanisms of Systemic Lupus Erythematosus","volume":"17","author":"Dema","year":"2014","journal-title":"Discovery Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus Nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30546-X","article-title":"Novel Paradigms in Systemic Lupus Erythematosus","volume":"393","author":"Dorner","year":"2019","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.coi.2021.03.003","article-title":"Autoimmunity, IgE and FcepsilonRI-Bearing Cells","volume":"72","author":"Charles","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2664","article-title":"Reply to: Basophils From Humans With Systemic Lupus Erythematosus do Not Express MHC-II","volume":"18","author":"Charles","year":"2012","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2159","article-title":"Basophils and the T Helper 2 Environment can Promote the Development of Lupus Nephritis","volume":"16","author":"Charles","year":"2010","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"7969","DOI":"10.1038\/s41598-017-08516-7","article-title":"Basophils Contribute to Pristane-Induced Lupus-Like Nephritis Model","volume":"7","author":"Dema","year":"2017","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41467-018-03129-8","article-title":"Prostaglandin D2 Amplifies Lupus Disease Through Basophil Accumulation in Lymphoid Organs","volume":"9","author":"Pellefigues","year":"2018","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.02.008","article-title":"Lyn Kinase Controls Basophil GATA-3 Transcription Factor Expression and Induction of Th2 Cell Differentiation","volume":"30","author":"Charles","year":"2009","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140066","article-title":"Immunoglobulin E Plays an Immunoregulatory Role in Lupus","volume":"211","author":"Dema","year":"2014","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e90424","DOI":"10.1371\/journal.pone.0090424","article-title":"Autoreactive IgE is Prevalent in Systemic Lupus Erythematosus and is Associated With Increased Disease Activity and Nephritis","volume":"9","author":"Dema","year":"2014","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e65767","DOI":"10.1371\/journal.pone.0065767","article-title":"Inverse Agonist and Pharmacochaperone Properties of MK-0524 on the Prostanoid DP1 Receptor","volume":"8","author":"Labrecque","year":"2013","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1124\/mol.105.017681","article-title":"On the Mechanism of Interaction of Potent Surmountable and Insurmountable Antagonists With the Prostaglandin D2 Receptor CRTH2","volume":"69","author":"Mathiesen","year":"2006","journal-title":"Mol Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.10.013","article-title":"Safety and Efficacy of the Prostaglandin D2 Receptor Antagonist AMG 853 in Asthmatic Patients","volume":"131","author":"Busse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1074-7613(00)80511-7","article-title":"Characterization of the B Lymphocyte Populations in Lyn-Deficient Mice and the Role of Lyn in Signal Initiation and Down-Regulation","volume":"7","author":"Chan","year":"1997","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.3.981","article-title":"Cutting Edge: Agonistic Effect of Indomethacin on a Prostaglandin D2 Receptor, CRTH2","volume":"168","author":"Hirai","year":"2002","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.074823","article-title":"Effects of Prostaglandin D(2) and 5-Lipoxygenase Products on the Expression of CD203c and CD11b by Basophils","volume":"312","author":"Monneret","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201344254","article-title":"CD41 is a Reliable Identification and Activation Marker for Murine Basophils in the Steady State and During Helminth and Malarial Infections","volume":"44","author":"Bakocevic","year":"2014","journal-title":"Eur J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2008.03154.x","article-title":"CD200R Surface Expression as a Marker of Murine Basophil Activation","volume":"39","author":"Torrero","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90171-X","article-title":"Multiple Defects in the Immune System of Lyn-Deficient Mice, Culminating in Autoimmune Disease","volume":"83","author":"Hibbs","year":"1995","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90126-4","article-title":"Impaired Proliferation of Peripheral B Cells and Indication of Autoimmune Disease in Lyn-Deficient Mice","volume":"3","author":"Nishizumi","year":"1995","journal-title":"Immunity"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1621","article-title":"Basophils Enhance Immunological Memory Responses","volume":"9","author":"Denzel","year":"2008","journal-title":"Nat Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002319","article-title":"Basophils Support the Survival of Plasma Cells in Mice","volume":"185","author":"Rodriguez Gomez","year":"2010","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy245","article-title":"Basophil Involvement in Lupus Nephritis: A Basis for Innovation in Daily Care","volume":"34","author":"Charles","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2013.10.003","article-title":"The Deleterious Role of Basophils in Systemic Lupus Erythematosus","volume":"25","author":"Pellefigues","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa263","article-title":"CD62L on Blood Basophils: A First Pre-Treatment Predictor of Remission in Severe Lupus Nephritis","volume":"36","author":"Halfon","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/art.40828","article-title":"Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus","volume":"71","author":"Hasni","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.11.009","article-title":"The Kaleidoscope of Glucorticoid Effects on Immune System","volume":"10","author":"Zen","year":"2011","journal-title":"Autoimmun Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00291","article-title":"Animal Models of Interferon Signature Positive Lupus","volume":"6","author":"Zhuang","year":"2015","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.824686\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:40:49Z","timestamp":1649076049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.824686\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2022.824686"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.824686","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]},"article-number":"824686"}}